The latest announcement is out from Septerna, Inc. ( (SEPN) ).

(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 ...

Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

NasdaqGM:SEPN 1 Year Share Price vs Fair Value Explore Septerna's Fair Values from the Community and select ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Investing.com -- Septerna, Inc. (NASDAQ: SEPN ), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, saw its shares fall 4.3% after reporting a widened net loss for ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25Record backlog of $1.40 billion; up6% year-over-yearQ4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted ...